Category
Australia
9 articles
TGA Reform Priorities for 2027: Accelerating Access to Medicines for Australians
Australia's Therapeutic Goods Administration faces mounting pressure to modernise its approval pathways, expand biosimilar uptake, close the digital therapeutics regulatory gap, and strengthen post-market surveillance. A policy analysis of the reform agenda for 2027.
Australia's Bulk Billing Crisis: Why Medicare Is Failing and What Needs to Change
Bulk billing rates for GP visits fell from roughly 88% in 2022 to 76% in 2024. A policy analysis of rebate indexation failures, the GP workforce crisis, out-of-pocket cost inequity, and the specific reforms needed to restore universal access to primary care.
Mental Health Medicare Reform in Australia: What's Working, What's Failing, and What Must Change
Australia's Better Access scheme has improved mental health care for many, but the 2023 reversal of 20 subsidised sessions, persistent cost barriers, workforce shortages, and system gaps leave too many people undertreated. A policy analysis of what reform is needed and why.
Preventive Health Funding in Australia: The Policy Case for Investment
Australia spends roughly 1.8% of total health expenditure on prevention versus the WHO 5% benchmark. A policy analysis of underinvestment, return on investment evidence, and costed reform proposals for 2026 and beyond.
TGA Regulation of Peptides in Australia: What Patients and Clinicians Need to Know
Australia's Therapeutic Goods Administration classifies peptides under a complex scheduling framework. This guide explains TGA peptide schedules, the March 2025 BPC-157 rescheduling, compounding pharmacy access, and what 'research use' means legally.
Bariatric Surgery Access in Australia: Policy Failures, Equity Gaps, and the Case for Reform
Australia's bariatric surgery system is two-tiered, inequitable, and failing hundreds of thousands of people with severe obesity. A policy analysis of access barriers, public waitlist failures, the economic case for expanded funding, and the role of GLP-1 medications in reshaping the surgical pipeline.
BPC-157 Schedule 4 in Australia: What the TGA Rescheduling Means and What Comes Next
A detailed policy and science analysis of Australia's TGA decision to reschedule BPC-157 to Schedule 4 in March 2025 — regulatory rationale, clinical implications, and the research evidence for this peptide.
Medicare and PBS Reform for Obesity Treatment: What Australia Needs to Do
Australia's PBS coverage of obesity medications is inadequate, inequitable, and out of step with the clinical evidence. A policy analysis of the case for expanded PBS listing of GLP-1 receptor agonists and what reform should look like.
Metabolic Syndrome in Australia: The Policy Gap Between Evidence and Action
Australia's metabolic syndrome burden is large, growing, and poorly addressed by current Medicare and public health policy. An evidence-based analysis of the gap between what the research shows and what the health system delivers.